4319-77-1

Basic information

• Product Name: 5-Bromo-4,6-dimethoxypyrimidine ,97%
• Synonyms: 5-Bromo-4,6-dimethoxypyrimidine ,97%
• CAS NO: 4319-77-1
• Molecular Formula: C₆H₇BrN₂O₂
• Molecular Weight: 219.04
• Mol File: 4319-77-1.mol
• Article Data: 3

Chemical Properties

• Melting Point: 149-151℃
• Boiling Point: 288℃
• Flash Point: 128℃
• Appearance: /
• Density: 1.563
• Vapor Pressure: 0.00418mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -0.03±0.26(Predicted)
• CAS DataBase Reference: 5-Bromo-4,6-dimethoxypyrimidine ,97%(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-4,6-dimethoxypyrimidine ,97%(4319-77-1)
• EPA Substance Registry System: 5-Bromo-4,6-dimethoxypyrimidine ,97%(4319-77-1)

Safety Data

• Statements: 34
• Safety Statements: 16-26-36/37/39-45
• RIDADR: 1759
• Hazardous Substances Data: 4319-77-1(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C6H7BrN2O2/c1-10-5-4(7)6(11-2)9-3-8-5/h3H,1-2H3

Upstream product

• 5270-94-0 4,6-dimethoxypyrimidine 
• 68797-61-5 5-bromo-4,6-dichloropyrimidine 
• 124-41-4 sodium methylate 

Downstream Products

• 96228-66-9 4,6-dimethoxy-5-(3,4-dinitrophenyl)pyrimidine 

Relevant articles and documents

COMPOUNDS AS MODULATORS OF ROR GAMMA

The present invention encompasses compounds of the formula (I)(I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Triazolopyrimidine cannabinoid receptor 1 antagonists

The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.